Last $0.13 USD
Change Today 0.00 / 0.00%
Volume 0.0
REON On Other Exchanges
Symbol
Exchange
OTC BB
As of 8:10 PM 04/15/14 All times are local (Market data is delayed by at least 15 minutes).

resolute oncology inc (REON) Snapshot

Open
$0.13
Previous Close
$0.13
Day High
$0.13
Day Low
$0.13
52 Week High
04/19/13 - $1.01
52 Week Low
03/4/14 - $0.12
Market Cap
5.4M
Average Volume 10 Days
2.0K
EPS TTM
--
Shares Outstanding
41.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RESOLUTE ONCOLOGY INC (REON)

Related News

No related news articles were found.

resolute oncology inc (REON) Related Businessweek News

No Related Businessweek News Found

resolute oncology inc (REON) Details

Resolute Oncology Inc., a development stage company, focusing on pharmaceutical business. The company sells cancer products in Germany. It also has rights to develop and commercialize Pegylated Granulocyte Colony-Stimulating Factor, a biosimilar therapeutic protein product under a license agreement with Reliance Life Sciences Limited. The company was formerly known as Pequot Resources, Inc. and changed its name to Resolute Oncology Inc. in January 2013. Resolute Oncology Inc. was incorporated in 2009 and is based in Sherman Oaks, California.

resolute oncology inc (REON) Top Compensated Officers

Chief Executive Officer, President, Chief Fin...
Total Annual Compensation: --
Compensation as of Fiscal Year 2012.

resolute oncology inc (REON) Key Developments

Resolute Oncology Inc. announced delayed annual 10-K filing

On 04/01/2014, Resolute Oncology Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Resolute Oncology Inc. to Announce Management Appointments

Resolute Oncology Inc. entered into binding term sheet with Update Pharma Inc. for a possible merger. The new agreed has Resolute Oncology Inc. continue to operate as Resolute Oncology Inc. and will survive as the sole entity. William Garner will join the Board of Directors, John Rothman and Sean Maenpaa shall be engaged by Resolute as CEO and Chief Commercial Officer respectively. Their employment will be for a minimum of 2 years, the details to be defined in an Employment Agreement for each and included in the definitive merger documentation.

Resolute Oncology Inc. announced delayed 10-Q filing

On 08/14/2013, Resolute Oncology Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REON:US $0.13 USD 0.00

REON Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for REON.
View Industry Companies
 

Industry Analysis

REON

Industry Average

Valuation REON Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.1x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESOLUTE ONCOLOGY INC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.